{"id":829504,"date":"2025-03-25T09:09:53","date_gmt":"2025-03-25T13:09:53","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/truist-securities-strengthens-its-biotech-equity-research-coverage\/"},"modified":"2025-03-25T09:09:53","modified_gmt":"2025-03-25T13:09:53","slug":"truist-securities-strengthens-its-biotech-equity-research-coverage","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/truist-securities-strengthens-its-biotech-equity-research-coverage\/","title":{"rendered":"Truist Securities strengthens its biotech equity research coverage"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n Danielle Brill<\/span> joins firm’s growing sales, trading, and research team<\/i>\n <\/p>\n

\n
\n ATLANTA<\/span>
\n <\/span>, March 25, 2025<\/span><\/span> \/PRNewswire\/ — Truist Securities announced today that Danielle Brill<\/span> has joined the firm as managing director, strengthening its equity research coverage in the biotechnology sector. Brill is the latest addition to Truist Securities, as the firm continues to expand its equity platform to broaden its capabilities in high-growth industries.<\/p>\n

\n

\n
\n \"Danielle
\n <\/a>\n <\/p>\n<\/p><\/div>\n

“Biotech continues to experience rapid evolution with new treatments and technologies, backed by compelling trial data, growing the market,” said Mary Stroth<\/span>, head of equity sales, trading, and research for Truist Securities. “Danielle’s unique insights and analysis will complement our existing team as we advise our institutional clients to navigate factors that impact their investment strategies such as product innovation, loss of exclusivity, and new adjacency use cases.”<\/p>\n

Brill’s coverage will complement the research from Truist Securities’ existing biotech and specialty pharma analysts, including Asthika Goonewardene, Joon Lee<\/span>, Srikripa Devarakonda<\/span>, Nicole Germino<\/span>, and Les Sulewski<\/span>.<\/p>\n

Prior to joining Truist Securities, Brill was a research analyst at Raymond James, where her coverage focused on neurology, hematology, and autoimmune diseases. She also served in research roles at Piper Sandler and Needham & Co. Brill’s experience includes time as a clinical pharmacist at Mount Sinai and bench research at Columbia University<\/span>. Brill earned a Bachelor of Science in human biology from Michigan State University<\/span> and a Doctorate of Pharmacy from Rutgers University<\/span>.<\/p>\n

“I am thrilled to join Truist Securities and collaborate with such a talented team,” said Brill. “I look forward to bringing my experience in biotech research to help drive continued growth and success at the firm. This is a fantastic opportunity, and I can’t wait to make a meaningful impact.”<\/p>\n

Brill is one of the latest additions to Truist Securities’ growing equity sales, trading, and research team.<\/p>\n